| A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy (NCT01840943) | Xian-Janssen Pharmaceutical Ltd. | 2013-06-01 |
| First Line Ovarian Cancer Treatment - Cohort Study (NCT01832415) | ARCAGY/ GINECO GROUP | 2013-04-01 |
| To Evaluate Plasmajet in Achieving Complete Cytoreduction of Advanced EOC- Initial Feasibility Study (NCT02376231) | Dr Thumuluru Kavitha Madhuri | 2013-03-01 |
| VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT01666444) | Celgene | 2012-10-31 |
| Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer (NCT01680575) | Asan Medical Center | 2012-09-01 |
| Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer (NCT01681368) | National Cancer Institute (NCI) | 2012-08-15 |
| Phase III Trial of Stage I Ovarian Cancer After Surgery (NCT04063527) | Japanese Gynecologic Oncology Group | 2012-07-20 |
| A Study LY2228820 for Recurrent Ovarian Cancer (NCT01663857) | Eli Lilly and Company | 2012-07-01 |
| Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer (NCT02681432) | PEDRO VILLAREJO CAMPOS | 2012-01-01 |
| Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment (NCT01521143) | Prima BioMed Ltd | 2012-01-01 |
| Research on Nutritional Risk Indexes and Inflammatory Indicators in Postoperative Complications and Prognosis of Epithelial Ovarian Cancer Patients (NCT06483399) | Qinglei Gao | 2012-01-01 |
| Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study (NCT01617629) | Prima BioMed Ltd | 2011-12-01 |
| A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers (NCT01447706) | Merrimack Pharmaceuticals | 2011-10-01 |
| FES-PET to Determine ER-expression in Epithelial Ovarian Cancer (NCT01439490) | University Medical Center Groningen | 2011-08-01 |
| Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Stand (NCT01549925) | University of Utah | 2011-01-01 |
| Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer (NCT01238770) | Priv.-Doz. Dr. med. Joachim Rom | 2010-11-01 |
| Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer (NCT01164995) | The Netherlands Cancer Institute | 2010-07-01 |
| Ovarian Cancer Vaccine for Patients in Remission (NCT01068509) | Prima BioMed Ltd | 2010-07-01 |
| Neoadjuvant Therapy for Ovarian Cancer (NCT01146795) | Jason D. Wright | 2010-05-17 |
| Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial (NCT01506856) | Gynecologic Oncology Trial & Investigation Consortium | 2010-05-01 |
| Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer (NCT01095367) | University of British Columbia | 2010-04-01 |
| Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer (NCT01091636) | National Cancer Center, Korea | 2010-03-01 |
| An Open Label Extension Study of the Efficacy of MORAb-003 (NCT01018563) | Morphotek | 2010-01-13 |
| Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel (NCT01000896) | AstraZeneca | 2010-01-01 |
| A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women (NCT01121640) | Fred Hutchinson Cancer Center | 2009-11-01 |
| Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer (NCT01004380) | Morphotek | 2009-11-01 |
| Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT (NCT01276574) | Turku University Hospital | 2009-10-01 |
| A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer (NCT01773889) | The University of Texas Health Science Center at San Antonio | 2009-06-01 |
| Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type (NCT00861120) | Vejle Hospital | 2009-04-01 |
| Study of Paclitaxel in Patients With Ovarian Cancer (NCT00989131) | Oasmia Pharmaceutical AB | 2009-02-01 |
| Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer (NCT00850772) | Queensland Centre for Gynaecological Cancer | 2009-01-01 |
| Prevention of Ovarian Cancer in Women Participating in Mammography (NCT01851109) | Fred Hutchinson Cancer Center | 2008-07-01 |
| Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00616941) | Ludwig Institute for Cancer Research | 2008-03-01 |
| Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study (NCT00968799) | Cantonal Hospital of St. Gallen | 2008-02-01 |
| Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer (NCT00563836) | Neovii Biotech | 2007-11-01 |
| Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors (NCT00561795) | GlaxoSmithKline | 2007-09-01 |
| A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer (NCT00880360) | The University of Texas Health Science Center at San Antonio | 2007-02-01 |
| Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer (NCT00889733) | University Health Network, Toronto | 2007-02-01 |
| Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer (NCT00408603) | Sunesis Pharmaceuticals | 2006-12-20 |
| Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer (NCT00281515) | AGO Study Group | 2006-01-01 |
| Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers (NCT00086567) | National Cancer Institute (NCI) | 2005-12-12 |
| Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer (NCT00314678) | John P. Fruehauf | 2005-09-01 |
| A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment (NCT00421889) | Valerio Therapeutics | 2005-08-01 |
| Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO) (NCT00538603) | King Faisal Specialist Hospital & Research Center | 2005-06-01 |
| Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer (NCT00428766) | Morphotek | 2005-06-01 |
| Women Surviving Ovarian Cancer (NCT00596349) | Memorial Sloan Kettering Cancer Center | 2004-11-01 |
| Pathogenic Variants in Homologous Recombination Repair Genes in Patients With Epithelial Ovarian Cancer (NCT04716374) | Hellenic Cooperative Oncology Group | 2004-01-01 |
| Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer (NCT00490711) | Eli Lilly and Company | 2003-07-01 |
| Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma (NCT00226915) | Japanese Gynecologic Oncology Group | 2003-04-01 |